Immuneering (NASDAQ:IMRX) Issues Quarterly Earnings Results

Immuneering (NASDAQ:IMRX) announced its earnings results on Friday. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.09, FiscalAI reports.

Immuneering Price Performance

Shares of NASDAQ:IMRX traded up $0.02 during trading on Friday, reaching $5.16. The company had a trading volume of 639,914 shares, compared to its average volume of 1,332,904. The firm has a market capitalization of $333.85 million, a price-to-earnings ratio of -3.74 and a beta of 0.37. The stock’s fifty day moving average price is $5.35 and its 200 day moving average price is $5.70. Immuneering has a fifty-two week low of $1.29 and a fifty-two week high of $10.08.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on IMRX shares. Wall Street Zen raised shares of Immuneering from a “sell” rating to a “hold” rating in a research note on Sunday, April 19th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Immuneering in a research note on Monday, March 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Immuneering presently has an average rating of “Moderate Buy” and an average target price of $16.50.

Institutional Trading of Immuneering

Several hedge funds and other institutional investors have recently made changes to their positions in IMRX. Jane Street Group LLC purchased a new stake in shares of Immuneering in the 1st quarter worth about $32,000. Geode Capital Management LLC raised its holdings in Immuneering by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after acquiring an additional 4,458 shares during the last quarter. XTX Topco Ltd purchased a new stake in Immuneering in the 2nd quarter valued at about $90,000. Bridgeway Capital Management LLC grew its holdings in Immuneering by 57.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after buying an additional 35,000 shares during the period. Finally, Corient Private Wealth LLC acquired a new position in shares of Immuneering in the 2nd quarter valued at $215,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.